Abstract
Disclosed herein is a technology to perform programmable RNA editing at single-nucleotide resolution using RNA-targeting CRISPR/Cas9. This approach, which Applicants have termed “Cas9-directed RNA editing” or “CREDIT,” provides a means to reversibly alter genetic information in a temporal manner, unlike traditional CRISPR/Cas9 driven genomic engineering which relies on permanently altering DNA sequence.
Original language | English (US) |
---|---|
Patent number | US20230053915A1 |
Priority date | 7/11/22 |
Filing date | 7/11/22 |
State | Published - Feb 23 2023 |